First Time Loading...
L

Lucid Diagnostics Inc
NASDAQ:LUCD

Watchlist Manager
Lucid Diagnostics Inc
NASDAQ:LUCD
Watchlist
Price: 0.7965 USD -0.31% Market Closed
Updated: Apr 20, 2024

Intrinsic Value

LUCD's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Lucid Diagnostics, Inc. develops medical testing devices. [ Read More ]

The intrinsic value of one LUCD stock under the Base Case scenario is 2.6245 USD. Compared to the current market price of 0.7965 USD, Lucid Diagnostics Inc is Undervalued by 70%.

Key Points:
LUCD Intrinsic Value
Base Case
2.6245 USD
Undervaluation 70%
Intrinsic Value
Price
L
Worst Case
Base Case
Best Case

Valuation Backtest
Lucid Diagnostics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling LUCD stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Lucid Diagnostics Inc

Provide an overview of the primary business activities
of Lucid Diagnostics Inc.

What unique competitive advantages
does Lucid Diagnostics Inc hold over its rivals?

What risks and challenges
does Lucid Diagnostics Inc face in the near future?

Has there been any significant insider trading activity
in Lucid Diagnostics Inc recently?

Summarize the latest earnings call
of Lucid Diagnostics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Lucid Diagnostics Inc.

Provide P/S
for Lucid Diagnostics Inc.

Provide P/E
for Lucid Diagnostics Inc.

Provide P/OCF
for Lucid Diagnostics Inc.

Provide P/FCFE
for Lucid Diagnostics Inc.

Provide P/B
for Lucid Diagnostics Inc.

Provide EV/S
for Lucid Diagnostics Inc.

Provide EV/GP
for Lucid Diagnostics Inc.

Provide EV/EBITDA
for Lucid Diagnostics Inc.

Provide EV/EBIT
for Lucid Diagnostics Inc.

Provide EV/OCF
for Lucid Diagnostics Inc.

Provide EV/FCFF
for Lucid Diagnostics Inc.

Provide EV/IC
for Lucid Diagnostics Inc.

Show me price targets
for Lucid Diagnostics Inc made by professional analysts.

What are the Revenue projections
for Lucid Diagnostics Inc?

How accurate were the past Revenue estimates
for Lucid Diagnostics Inc?

What are the Net Income projections
for Lucid Diagnostics Inc?

How accurate were the past Net Income estimates
for Lucid Diagnostics Inc?

What are the EPS projections
for Lucid Diagnostics Inc?

How accurate were the past EPS estimates
for Lucid Diagnostics Inc?

What are the EBIT projections
for Lucid Diagnostics Inc?

How accurate were the past EBIT estimates
for Lucid Diagnostics Inc?

Compare the revenue forecasts
for Lucid Diagnostics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Lucid Diagnostics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Lucid Diagnostics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Lucid Diagnostics Inc compared to its peers.

Compare the P/E ratios
of Lucid Diagnostics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Lucid Diagnostics Inc with its peers.

Analyze the financial leverage
of Lucid Diagnostics Inc compared to its main competitors.

Show all profitability ratios
for Lucid Diagnostics Inc.

Provide ROE
for Lucid Diagnostics Inc.

Provide ROA
for Lucid Diagnostics Inc.

Provide ROIC
for Lucid Diagnostics Inc.

Provide ROCE
for Lucid Diagnostics Inc.

Provide Gross Margin
for Lucid Diagnostics Inc.

Provide Operating Margin
for Lucid Diagnostics Inc.

Provide Net Margin
for Lucid Diagnostics Inc.

Provide FCF Margin
for Lucid Diagnostics Inc.

Show all solvency ratios
for Lucid Diagnostics Inc.

Provide D/E Ratio
for Lucid Diagnostics Inc.

Provide D/A Ratio
for Lucid Diagnostics Inc.

Provide Interest Coverage Ratio
for Lucid Diagnostics Inc.

Provide Altman Z-Score Ratio
for Lucid Diagnostics Inc.

Provide Quick Ratio
for Lucid Diagnostics Inc.

Provide Current Ratio
for Lucid Diagnostics Inc.

Provide Cash Ratio
for Lucid Diagnostics Inc.

What is the historical Revenue growth
over the last 5 years for Lucid Diagnostics Inc?

What is the historical Net Income growth
over the last 5 years for Lucid Diagnostics Inc?

What is the current Free Cash Flow
of Lucid Diagnostics Inc?

Financials

Balance Sheet Decomposition
Lucid Diagnostics Inc

Current Assets 22.1m
Cash & Short-Term Investments 18.9m
Receivables 45k
Other Current Assets 3.1m
Non-Current Assets 5.2m
PP&E 2.6m
Intangibles 1.4m
Other Non-Current Assets 1.1m
Current Liabilities 29.4m
Accounts Payable 1.1m
Accrued Liabilities 4.9m
Short-Term Debt 23.3m
Non-Current Liabilities 199k
Other Non-Current Liabilities 199k
Efficiency

Earnings Waterfall
Lucid Diagnostics Inc

Revenue
2.4m USD
Cost of Revenue
-6m USD
Gross Profit
-3.6m USD
Operating Expenses
-44.9m USD
Operating Income
-48.5m USD
Other Expenses
-4.2m USD
Net Income
-52.7m USD

Free Cash Flow Analysis
Lucid Diagnostics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

LUCD Profitability Score
Profitability Due Diligence

Lucid Diagnostics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
Negative Operating Income
Negative Net Income
21/100
Profitability
Score

Lucid Diagnostics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

LUCD Solvency Score
Solvency Due Diligence

Lucid Diagnostics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Low D/E
Positive Net Debt
Long-Term Solvency
Short-Term Solvency
46/100
Solvency
Score

Lucid Diagnostics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LUCD Price Targets Summary
Lucid Diagnostics Inc

Wall Street analysts forecast LUCD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LUCD is 3.91 USD with a low forecast of 2.525 USD and a high forecast of 8.4 USD.

Lowest
Price Target
2.525 USD
217% Upside
Average
Price Target
3.91 USD
391% Upside
Highest
Price Target
8.4 USD
955% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

LUCD Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

LUCD Price
Lucid Diagnostics Inc

1M 1M
-28%
6M 6M
-37%
1Y 1Y
-49%
3Y 3Y
-93%
5Y 5Y
-93%
10Y 10Y
-93%
Annual Price Range
0.7965
52w Low
0.7965
52w High
1.78
Price Metrics
Average Annual Return -64.46%
Standard Deviation of Annual Returns 12.75%
Max Drawdown -93%
Shares Statistics
Market Capitalization 38.2m USD
Shares Outstanding 47 999 100
Percentage of Shares Shorted 2.92%

LUCD Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Lucid Diagnostics Inc

Country

United States of America

Industry

Health Care

Market Cap

38.2m USD

Dividend Yield

0%

Description

Lucid Diagnostics, Inc. develops medical testing devices. The company is headquartered in New York City, New York. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). Its products include EsoCheck and EsoGuard. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in an office procedure. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. EsoGuard is a bisulfite-converted next generation sequencing (NGS) deoxyribonucleic acid (DNA) assay performed on surface esophageal cells collected with EsoCheck. The firm is a subsidiary of PAVmed Inc.

Contact

NEW YORK
New York City
One Grand Central Place, Suite 4600, Suite 4600
+12129494319.0
https://www.luciddx.com/

IPO

2021-10-14

Employees

-

Officers

Chairman & CEO
Dr. Lishan Aklog M.D.
President & COO
Mr. Shaun M. O'Neill M.B.A.
Chief Financial Officer
Mr. Dennis M. McGrath CPA
Cofounder & Strategic Advisor, Member of the Medical Advisor Board
Dr. Sanford D. Markowitz M.D., Ph.D.
Cofounder, Strategic Advisor & Member of Medical Advisory Board
Dr. Amitabh Chak M.D.
Chief Technology Officer
Richard D. Yazbeck
Show More
Chief Scientific Officer
Dr. Suman M. Verma M.D., Ph.D.
Chief Compliance Officer
Dr. Brian J. deGuzman M.D.
General Counsel & Secretary
Mr. Michael Adam Gordon
Show Less

See Also

Discover More
What is the Intrinsic Value of one LUCD stock?

The intrinsic value of one LUCD stock under the Base Case scenario is 2.6245 USD.

Is LUCD stock undervalued or overvalued?

Compared to the current market price of 0.7965 USD, Lucid Diagnostics Inc is Undervalued by 70%.